Testosterone

Sustanon, Andriol, Testoviron e altri

1. Abraham D., Carpenter P. C., Mayo Clinic Proc., 1997, 72, 1051.

2. ASCO – American Society of Clinical Oncology, 2007, 1-5 giugno, Chicago.

3. Baillargeon J. et al., Ann Pharmacother., 2014, 48 (9), 1138.

4. Bhasin S. et al., J. Clin. Endocrinol. Metab., 2 2006, 91, 1995.

5. Buster J. E. et al., Obstet. Gynecol., 2005, 105, 944.

6. Calof O.M. et al., J. Gerontol. A. Biol. Sci. Med. Sci., 2005, 60 (11), 4151.

7. Conway A.J. et al., Med. J. Aust., 2000, 172, 220.

8. Corona G. et al., Exp. Opin. Drug Safety, 2014, 13 (10), 1327.

9. Crawford B.A. et al., J. Clin. Endocrinol. Metab., 2003, 88, 3167.

10. De Waal W.J. et al., Arch. Dis. Child., 1995, 73, 311.

11. Finkle W.D. et al., PloS One, 2014, 9 (1), e85805.

12. Food and Drug Administration - FDA, Drug safety and Availability, 2014, 19 giugno disponibile online http://www.fda.gov/drugs/drugsafety/ucm401746.htm

13. Friederich E.G., Kalra P. S. , NEJM, 1984, 310, 488.

14. Grinspoon S. et al., Ann. Int. Med., 1998, 129, 18.

15. Isidori A. M. et al., Clin. Endocrinol., 2005, 63, 381.

16. Lancet, 1990, 955, 8721.

17. Misra R., Anderson D. C., BMJ, 1989, 299 , 834.

18. Morgentaler A. et al., Mayo Clin. Proc., 2015, 90 (2), 224

19. Simon J. et al., Clin. Endocrinol. Metab., 2005, 90, 5226.

20. Storer T.W. et al., ICE/ENDO, 2014, giugno.

21. Tamimi M.R. et al., Arch. Intern. Med., 2006, 166, 1483.

22. Tracz M.J. et al., J. Clin. Endocrinol. Metab., 2006, 91, 2011.

23. Vigen R. et al., JAMA, 2013, 310 (17), 1829.

24. Voelker R., JAMA, 2009, 301, 2428.

25. Wang C. et al., J. Clin. Endocrinol. Metab., 2000, 85, 2839.

26. Wang C. et al., Clin Endocrinol., 2001, 54, 739.

Link

1) “Children’s Exposure to Testosterone Gel Spurs FDA to Order Boxed Label Warning” JAMA, 2009, 301, 2428.